medigraphic.com
ISSN 0185-3325 (Print)
Órgano Oficial del Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz

2009, Number 1

<< Back Next >>

Salud Mental 2009; 32 (1)

Melatonin reduces neuronal loss and cytoskeletal deterioration: implications for psychiatry

Reiter RJ, Benitez-King G

Language: Spanish
References: 104
Page: 3-11
PDF size: 122.57 Kb.


ABSTRACT

This review article summarizes the potential role of circadian rhythmicity and melatonin in psychiatric disorders. The melatonin rhythm, with high blood levels at night and low values during the day, is a reflection of the biological clock, i.e., the suprachiasmatic nucleus (SCN). The SCN receive information about the prevailing light: dark conditions from specialized ganglion cells (only 1-2% of the total ganglion cells) in the retina. These unique cells contain a newly-discovered photopigment, melanopsin, which responds to a rather narrow band width of light that peaks at roughly 480 nm. The axons of these ganglion cells project via the retinohypothalamic tract through the optic nerve to the SCN, located just above the optic chiasm in the anterior hypothalamus. Via this pathway, light detected by the retina synchronizes the circadian clock to precisely 24 hours. In the absence of light, i.e., darkness, the SCN signals the pineal gland to produce melatonin via a complex neural pathway that involves fibers that project from the hypothalamus to the preganglionic sympathetic neurons in the intermediolateral cell column of the upper thoracic cord. Axons of these neurons exit the spinal cord to eventually synapse on neurons in the superior cervical ganglia. Then, postganglionic fibers convey the information to the pineal gland mediating the nighttime rise in melatonin synthesis. Because melatonin is only elevated at night, it is referred to as the «chemical expression of darkness». Disturbances in the rhythmicity of the biological clock and/or the melatonin rhythm likely contribute to psychophysiological disturbances and mood disorders. Major disturbances occur in circadian rhythmicity when light, which activates the SCN and inhibits melatonin production, is imposed during the normal dark period. Thus, even brief periods of light at night are readily detected by the specialized ganglion cells mentioned above; this sets off a chain of events that alter biological clock physiology and depresses nighttime melatonin levels when they should be elevated. Depressed circulating melatonin levels at night provide misinformation to all cells that can «read» the message. This misinformation contributes to alterations in mood and negative psychological feelings of well-being. Melatonin has several major functions which probably assist in protecting humans from psychiatric illnesses. This indoleamine is widely known as a sleep-promoting factor. As such, it reduces the latency to sleep onset and improves sleep hygiene. Melatonin has been tested for its beneficial effects on sleep in children with neurodevelopmental disabilities, in individuals with delayed sleep phase syndrome and in elderly patients with insomnia. In each of these situations, melatonin has proven to be beneficial. Sleep disturbances are often associated with and probably contribute to psychiatric illness.Melatonin is also a potent free radical scavenger and antioxidant. It, as well as several of its metabolites, are powerful protectors against oxidative stress and free radical-mediated, mitochondrial-dependent cellular apoptosis. Melatonin seems to be particularly effective in protecting the brain from oxidative mutilation and loss of cells resulting from apoptosis. Given that a variety of neurodegenerative diseases, e.g., Alzheimer disease, parkinsonism, amyotrophic lateral sclerosis, have a free radical component, it is assumed that melatonin may be useful in forestalling the consequences of these debilitating conditions and improving the psychological makeup of these patients. Preliminary clinical trials suggest melatonin will be useful in this regard. A major action of melatonin in the Central Nervous System is protection of the neuronal cytoskeleton from oxidative damage. Structural damage to the cytoskeleton is consequential in the function of neurons and is not uncommonly associated with psychological illness and with neurodegenerative diseases. For example, tauopathies (tau is an important cytoskeletal protein) contribute to neuropsychiatric disorders. Damage to the tau protein, resulting from the hyperphosphorylation of this important molecule, disrupts intraneuronal microtubules and alters synaptic physiology. The destruction of normal cytoskeletal function is often a result of excessive free radial generation. The free radical-mediated changes result in loss of neuronal polarization and cells die of apoptosis leading to neurobehavioral disorders and dementia. Given that melatonin is an antioxidant, it has been tested for its efficacy in reducing damage to the cytoskeleton as well as limiting the behavioral effects. In this cap acity melatonin has been found highly effective in reducing damage to essential cytoskeletal elements and improving neurobehavioral outcomes. Overall, melatonin may well find utility in reducing neural deterioration with age as well as improving the psychological wellbeing of individuals. Melatonin is an inexpensive non-toxic molecule which should be considered for use in a number of psychiatric diseases and circadian rhythm disorders.


REFERENCES

  1. Reiter RJ. Pineal melatonin: cell biology of its synthesis and of its physiological interactions. Endocr Rev 1991;12:151-180.

  2. Reiter J. Melatonin: the chemical expression of darkness. Molec Cell Endocrinol 1991;79:C153-C158.

  3. Schulz P. Biological clocks and the practice of psychiatry. Dialog Clin Neurosci 2007;9:237-255.

  4. Arendt J, Skene DJ, Middleton B, Lockley SW, Deacon S. Efficacy of melatonin treatment in jet lag, shift work and blindness. J Biol Rhythms 1997;12:604-617.

  5. Macher JP (editor). Dialogues Clinical Neuroscience. 2007;9:1-346.

  6. Reiter RJ. Oxidative damage in the central nervous system: protection by melatonin. Progr Neurobiol 1998;56:359-386.

  7. Benitez-King G. Melatonin as a cytoskeletal modulator: implications for cell physiology and disease. J Pineal Res 2006;40:1-9.

  8. Chou YH, Skalli O, Goldman RD. Intermediate filaments and cytoplasmic networking: new corrections and more functions. Curr Opin Cell Biol 1997; 9:49-53.

  9. Leon J, Acuna-Castroviejo D, Escames G, Tan DX, Reiter RJ. Melatonin mitigates mitochondrial malfunction. J Pineal Res 2005; 38:1-9.

  10. Jou MJ, Peng TI, Yu SB et al. Melatonin protects against common deletion of mitochondrial DNA-augmented mitochondrial oxidative stress and apoptosis. J Pineal Res 2007;43:389-403.

  11. Pandi-Perrumal SR, Zisapel N, Srinivasan V, Cardinali DP. Melatonin and sleep in aging population. Exp Gerontol 2005;40:911-925.

  12. Jan JE, Wasdell MB, Reiter RJ et al. Melatonin therapy in sleep disorders: recent advances, why it works, who are the candidates and how to treat. Curr Pediatr Rev 2007;3:214-224.

  13. Wu YH, Swaab DF. The human pineal and melatonin in aging and Alzheimer’s disease. J Pineal Res 2005;38:145-152.

  14. Shamir P, Laudon M, Barak Y et al. Melatonin improves sleep quality of patients with chronic schizophrenia. J Clin Psychiatr 2000;61:373-377.

  15. Zisapel N. Sleep and sleep disturbance: biological basis and clinical implications. Cell Molec Life Sci 2007; 64:1174-1186.

  16. Brzezinski A. Melatonin in humans. New Engl J Med 1997;336:186-195.

  17. Jan JE, Wasdell MB, Freeman RD, Bax M. Evidence supporting the use of melatonin in short gestation infants. J Pineal Res 2007;42:22-27.

  18. Reeder CE, Franklin M, Bromley TJ. Current landscape of insomnia in managed care. Am J Manag Care 2007;13(Supl 5):S112-S116.

  19. Armitage R. Sleep and circadian rhythms in mood disorders. Acta Psychiatr Psychosom Res 2007;433:104-115.

  20. Mellman TA. Sleep and anxiety disorders. Psychiatr Clin North Am 2006;29:1047-1058.

  21. Tan DX, Chen LD, Poeggeler B, Manchester LC, Reiter RJ. Melatonin: a potent endogenous hydroxyl radical scavenger. Endocrine J 1993;1:57-60.

  22. Reiter RJ. Melatonin: lowering the high price of free radicals. News Physiol Sci 2000;15:246-250.

  23. Tan DX, Manchester LC, Terron MP, Flores LJ, Reiter RJ. One molecule,many derivatives: a never-ending interaction of melatonin with reactive oxygen and reactive nitrogen species? J Pineal Res 2007;42:28-42.

  24. Reiter RJ, Paredes S, Korkmaz A, Jou MJ, Tan DX. Melatonin combats molecular terrorism at the mitochondrial level. Interdisc Toxicol 2008;1:137-149.

  25. Hardeland R. Antioxidative protection by melatonin. Endocrine 2005;27:119-130.

  26. Reiter RJ, Tan DX, Osuna C, Gitto E. Actions of melatonin in the reduction of oxidative stress. J Biomed Sci 2000;7:444-458.

  27. Rodriguez C, Mayo JC, Sainz RM et al. Regulation of antioxidant enzymes: a significant role for melatonin. J Pineal Res 2004;36:1-9.

  28. Tomas-Zapico C, Coto-Montes A. A proposed mechanism to explain the stimulatory effect of melatonin on antioxidative enzymes. J Pineal Res 2005;39:99-104.

  29. Lohr JB. Oxygen radicals and neuropsychiatric illness. Arch Gen Psychiatry 1991;48:1097-1106.

  30. Cadet JL, Kohler LA. Free radical mechanisms in schizophrenia and tardive dyskinesia. Neurosci Biobehav Sci 1994;18:457-467.

  31. Reiter RJ, Pablos MI, Agapito TT, Guerrero M. Melatonin in the context of the free radical theory of aging. Ann NY Acad Sci 1996;726:362-378.

  32. Pappolla MA, Chyan YJ, Poeggeler B et al. An assessment of the antioxidant and antiamyloidogenic actions of melatonin: implications for Alzheimer’s disease. J Neural Transm 2000;107:203-231.

  33. Mayo JC, Sainz RM, Tan DX, Antolin I, Rodriguez C et al. Melatonin and Parkinson’s disease. Endocrine 2005;27:169-178.

  34. Reiter RJ, Tan DX, Pappolla MA. Melatonin relieves the neural burden that contributes to dementias. Ann NY Acad Sci 2004;1035:179-196.

  35. Zhou J, Zhang S, Zhao X, Wei T. Melatonin impairs NADPH oxidase assembly and decreases superoxide anion production in microglia exposed to amyloid- β1-42. J Pineal Res 2008;45:157-165.

  36. Matsubara E, Bryant-Thomas T, Pacheco Quinto J et al. Melatonin increases survival and inhibits oxidative and amyloid pathology in a transgenic model of Alzheimer’s disease. J Neurochem 2003;85:1101-1108.

  37. Small BJ, Gagnon E, Robinson B. Early identification of cognitive deficits: preclinical Alzheimer’s disease and mild cognitive impairment. Geriatrics 2007;62:19-23.

  38. Cardinali DP, Brusco LI, Liberczuk C, Furio AM. The use of melatonin in Alzheimer’s disease. Neuroendocrinol Lett 2002;23(Supl 1):20-23.

  39. Cohen-Mansfield J, Garfinkel D, Lipson S. Melatonin for treatment of sundowning in elderly patients with dementia–a preliminary study. Arch Gerontol Geriatr 2000; 31:65-76.

  40. Mahlberg R, Kunz D, Sutej I, Kuhl KP, Hellweg R. Melatonin treatment of day-night rhythm disturbances and sundowning in Alzheimer’s disease: an open-label pilot study using actigraphy. J Clin Psychopharmacol 2004; 24:456-459.

  41. Brusco LI, Marquez M, Cardinali DP. Monozygotic twins with Alzheimer’s disease treated with melatonin: case report. J Pineal Res 1998;25:260-263.

  42. Asayama K, Yamadera H, Ito T et al. Double-blind study of melatonin effects on the sleep-wake rhythm, cognitive and non-cognitive functions in Alzheimer’s type dementia. J Nippon Med Sch 2003;70:334-341.

  43. Tan DX, Manchester LC, Reiter RJ, Qi W, Kim SJ et al. Melatonin protects hippocampal neurons in vivo against kainic acid-induced damage in mice. J Neurosci Res 1998; 54:382-389.

  44. Chung SY, Han SH. Melatonin attenuates kainic acid-induced hippocampal neurodegeneration and oxidative stress through microglial inhibition. J Pineal Res 2003;34:95-102.

  45. Lee SH, Chun W, Kong PJ et al. Sustained activation of Akt by melatonin contributes to the protection against kainic acid-induced neuronal death in hippocampus. J Pineal Res 2006;40:79-85.

  46. Cervantes M, Morali G, Letechipia-Vallejo G. Melatonin and ischemiareperfusion injury of the brain. J Pineal Res 2008;45:1-7.

  47. Allegra M, Reiter RJ, Tan DX, Gentile C, Tesoriere L et al. The chemistry of melatonin’s interaction with reactive species. J Pineal Res 2003;34:1-10.

  48. Maldonado MD, Murrillo-Cabezas F, Terron MP et al. The potential of melatonin in reducing morbidity-mortality after craniocerebral trauma. J Pineal Res 2007;42:1-11.

  49. Reiter RJ, Tan DX, Terron MP, Flores LJ, Czarnocki Z. Melatonin and its metabolites: new findings regarding their production and their radical scavenging actions. Acta Biochem Pol 2007;54:1-9.

  50. Furio AM, Brusco LI, Cardinali DP. Possible therapeutic value of melatonin in mild cognitive impairment: a retrospective study. J Pineal Res2007; 43:404-409.

  51. Cid-Arregui A, De HM, Dotti CG. Mechanisms of neuronal polarity.Neurobiol Aging 1995; 16:239-243.

  52. Dotti CG, Sullivan CA, Banker GA. The establishment of polarity by hippocampal neurons in culture. J Neurosci 1988;8:1454-1468.

  53. Benitez-King G, Ramirez-Rodriguez G, Ortiz L, Meza I. The neuronal cytoskeleton as a potential therapeutical target in neurodegenerative diseases and schizophrenia. Curr Drug Targets CNS Neurol Disord 2004;3:515-533.

  54. Jiménez-Rubio G, Bellon-Velasco, A., Ortiz-López L, Ramírez-Rodríguez G, Ortega-Soto H† et al. El neurocitoesqueleto: Un nuevo blanco terapéutico para el tratamiento de la depresión. Salud Mental 2007;30:1-10.

  55. Fletcher P. The missing link: a failure of fronto-hippocampal integration in schizophrenia. Nat Neurosci 1998;1:266-267.

  56. Bearden CE, Hoffman KM, Cannon TD. The neuropsychology and neuroanatomy of bipolar affective disorder: a critical review. Bipolar Disord 2001;3:106-150.

  57. Brambilla P, Glahn DC, Balestrieri M, Soares JC. Magnetic resonance findings in bipolar disorder. Psychiatr Clin North Am 2005;28:443-467.

  58. Stockmeier CA, Mahajan GJ, Konick LC, Overholser JC, Jurjus GJ et al.Cellular changes in the postmortem hippocampus in major depression. Biol Psychiatry 2004;56:640-650.

  59. Glantz LA, Lewis DA. Decreased dendritic spine density on prefrontal cortical pyramidal neurons in schizophrenia. Arch Gen Psychiatry 2000;57:65-73.

  60. Arnold SE. Cellular and molecular neuropathology of the parahippocampal region in schizophrenia. Ann NY Acad Sci 2000;911:275-292.

  61. Rajkowska G, Miguel-Hidalgo JJ, Wei J, Dilley G, Pittman SD et al. Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression. Biol Psychiatry 1999;45:1085-1098.

  62. Garey LJ, Ong WY, Patel TS, Kanani M, Davis A et al. Reduced dendritic spine density on cerebral cortical pyramidal neurons in schizophrenia. J Neurol Neurosurg Psychiatry 1998;65:446-453.

  63. Dent EW, Gertler FB. Cytoskeletal dynamics and transport in growth cone motility and axon guidance. Neuron 2003;40:209-227.

  64. Shea TB, Beermann ML. Respective roles of neurofilaments, microtubules,MAP1B, and tau in neurite outgrowth and stabilization. Mol Biol Cell 1994;5:863-875.

  65. McGlashan TH, Hoffman RE. Schizophrenia as a disorder of developmentally reduced synaptic connectivity. Arch Gen Psychiatry 2000;57:637-648.

  66. Law AJ, Weickert CS, Hyde TM, Kleinman JE, Harrison PJ. Reduced spinophilin but not microtubule-associated protein 2 expression in the hippocampal formation in schizophrenia and mood disorders: molecular evidence for a pathology of dendritic spines. Am J Psychiatry 2004; 161:1848-1855.

  67. Fossati P, Radtchenko A, Boyer P. Neuroplasticity: from MRI to depressive symptoms. Eur Neuropsychopharmacol 2004;14(Supl 5):S503-S510.

  68. Perry G, Friedman R, Kang DH, Manetto V, Utilio-Gambetti L et al.Antibodies to the neuronal cytoskeleton are elicited by Alzheimer paired helical filament fractions. Brain Res 1987;420:233-242.

  69. Eidenmuller J, Fath T, Hellwig A, Reed J, Sontag E et al. Structural and functional implications of tau hyperphosphorylation: information from phosphorylation-mimicking mutated tau proteins. Biochemistry 2000; 39:13166-13175.

  70. Avila J. Tau aggregation into fibrillar polymers: taupathies. FEBS Lett 2000;476:89-92.

  71. Brandt R, Lee G. Orientation, assembly, and stability of microtubule bundles induced by a fragment of tau protein. Cell Motil Cytoskeleton 1994;28:143-154.

  72. Gustke N, Trinczek B, Biernat J, Mandelkow EM, Mandelkow E. Domains of tau protein and interactions with microtubules. Biochemistry 1994;33:9511-9522.

  73. Alonso AD, Grundke-Iqbal I, Barra HS, Iqbal K. Abnormal phosphorylation of tau and the mechanism of Alzheimer neurofibrillary degeneration: sequestration of microtubule-associated proteins 1 and 2 and the disassembly of microtubules by the abnormal tau. Proc Natl Acad Sci USA 1997;94:298-303.

  74. Wang D, An SC, Zhang X. Prevention of chronic stress-induced depression-like behavior by inducible nitric oxide inhibitor. Neurosci Lett 2008;433:59-64.

  75. Grima G, Benz B, Parpura V, Cuenod M, Do KQ. Dopamine-induced oxidative stress in neurons with glutathione deficit: implication for schizophrenia. Schizophr Res 2003; 62:213-224.

  76. De la Monte SM, Neely TR, Cannon J, Wands JR. Oxidative stress and hypoxia-like injury cause Alzheimer-type molecular abnormalities in central nervous system neurons. Cell Mol Life Sci 2000;57:1471-1481.

  77. Yao JK, Reddy R, McElhinny LG, van Kammen DP. Reduced status of plasma total antioxidant capacity in schizophrenia. Schizophr Res 1998;32:1-8.

  78. Prilipko LL, Erin AN, Beliaev BS, Piatnitskii AN, Siuniakov SA. [Activation of lipid peroxidation in the bodies of schizophrenic and manic-depressive patients]. Zh Nevropatol Psikhiatr Im S S Korsakova 1987;87: 100-103.

  79. Khan MM, Evans DR, Gunna V, Scheffer RE, Parikh VV et al. Reduced erythrocyte membrane essential fatty acids and increased lipid peroxides in schizophrenia at the never-medicated first-episode of psychosis and after years of treatment with antipsychotics. Schizophr Res 2002;58:1-10.

  80. Bilici M, Efe H, Koroglu MA, Uydu HA, Bekaroglu M et al. Antioxidative enzyme activities and lipid peroxidation in major depression: alterations by antidepressant treatments. J Affect Disord 2001;64:43-51.

  81. Milzani A, DalleDonne I, Colombo R. Prolonged oxidative stress on actin.Arch Biochem Biophys 1997; 339:267-274.

  82. Sponne I, Fifre A, Drouet B, Klein C, Koziel V et al. Apoptotic neuronal cell death induced by the non-fibrillar amyloid-beta peptide proceeds through an early reactive oxygen species-dependent cytoskeleton perturbation 3. J Biol Chem 2003;278:3437-3445.

  83. Pollak D, Cairns N, Lubec G. Cytoskeleton derangement in brain of patients with Down syndrome, Alzheimer’s disease and Pick’s disease. J Neural Transm Suppl 2003; 149-158.

  84. Benítez-King G, Ortiz-López L, Jiménez-Rubio G. Melatonin precludes cytoskeletal collapse caused by hydrogen peroxide: participation of protein kinase C. Therapy 2005; 2:1-12.

  85. Borg J, London J. Copper/zinc superoxide dismutase overexpression promotes survival of cortical neurons exposed to neurotoxins in vitro. J Neurosci Res 2002; 70:180-189.

  86. Da Silva JS, Dotti CG. Breaking the neuronal sphere: regulation of the actin cytoskeleton in neuritogenesis. Nat Rev Neurosci 2002;3(9):694-704.

  87. Undamatla J, Szaro BG. Differential expression and localization of neuronal intermediate filament proteins within newly developing neurites in dissociated cultures of Xenopus laevis embryonic spinal cord. Cell Motil Cytoskeleton 2001;49:16-32.

  88. Reiter RJ, Tan DX, Osuna C, Gitto E. Actions of melatonin in the reduction of oxidative stress. A review. J Biomed Sci 2000;7:444-458.

  89. Benítez-King G. Melatonin as a cytoskeletal modulator: implications for cell physiology and disease. J Pineal Res 2006;40:1-9.

  90. Benítez-King G, Huerto-Delgadillo L, Antón-Tay F. Melatonin effects on the cytoskeletal organization of MDCK and neuroblastoma N1E-115 cells. J Pineal Res 1990;9:209-220.

  91. Huerto-Delgadillo L, Antón-Tay F, Benitez-King G. Effects of melatonin on microtubule assembly depend on hormone concentration: role of melatonin as a calmodulin antagonist. J Pineal Res 1994;17:55-62.

  92. Bellon A, Ortiz-Lopez L, Ramirez-Rodriguez G, Antón-Tay F, Benitez-King G. Melatonin induces neuritogenesis at early stages in N1E-115 cells through actin rearrangements via activation of protein kinase C and Rho-associated kinase. J Pineal Res 2007;42:214-221.

  93. Galili R, Mosberg, Gil-Ad I, Weizman A, Melamed E, Offen D. Haloperidol-induced neurotoxicity—possible implications for tardive dyskinesia. J Neural Transm 2000; 107:479-490.

  94. Mason RP, Fischer V. Possible role of free radical formation in druginduced agranulocytosis. Drug Saf 1992;7 Suppl 1:45-50.

  95. Gabai VL, Kabakov AE, Makarova I, Mosina VA, Mosin AF. [Fragmentation of Ehrlich ascites carcinoma DNA during influences causing aggregation of cytoskeletal proteins]. Biokhimiia 1994;59:551-558.

  96. Bialojan C, Takai A. Inhibitory effect of a marine-sponge toxin, okadaic acid, on protein phosphatases. Specificity and kinetics. Biochem J 1988;256:283-290.

  97. Arendt T, Holzer M, Bruckner MK, Janke C, Gartner U. The use of okadaic acid in vivo and the induction of molecular changes typical for Alzheimer’s disease. Neuroscience 1998;85:1337-1340.

  98. Benítez-King G, Tunez I, Bellon A, Ortiz GG, Antón-Tay F. Melatonin prevents cytoskeletal alterations and oxidative stress induced by okadaic acid in N1E-115 cells. Exp Neurol 2003;182:151-159.

  99. Jiménez-Rubio G, Benítez-King G, Ortiz-López L. Melatonin elicits neuritogenesis and reverses tau hyperphosphorylation in N1E-115 neuroblastoma cells treated with okadaic acid. In: Focus in neuroblastoma research. Fernandes AJ (ed). Hauppauge, NY: Nova Science Publishers; 2006; p. 99-117.

  100. Deng YQ, Xu GG, Duan P, Zhang Q, Wang JZ. Effects of melatonin on wortmannin-induced tau hyperphosphorylation. Acta Pharmacol Sin 2005;26:519-526.

  101. Liu SJ, Wang JZ. Alzheimer-like tau phosphorylation induced by wortmannin in vivo and its attenuation by melatonin. Acta Pharmacol Sin 2002;23:183-187.

  102. Wang XC, Zhang J, Yu X, Han L, Zhou ZT, et al. Prevention of isoproterenol-induced tau hyperphosphorylation by melatonin in the rat. Sheng Li Xue Bao 2005;57:7-12.

  103. Li XC, Wang ZF, Zhang JX, Wang Q, Wang JZ. Effect of melatonin on calyculin A-induced tau hyperphosphorylation. Eur J Pharmacol 2005;510:25-30.

  104. Shamir E, Barak Y, Shalman I, Laudon M, Zisapel N et al. Melatonin treatment for tardive dyskinesia: a double-blind, placebo-controlled, crossover study. Arch Gen Psychiatry 2001;58:1049-1052.




2020     |     www.medigraphic.com